210 related articles for article (PubMed ID: 8705327)
1. [High-resolution electrocardiography in monitoring myocardial damage after therapy with anthracyclines in children].
Mladosievicová B; Foltinová A; Bernadic M; Petrásová H; Hulín I
Bratisl Lek Listy; 1996 May; 97(5):289-97. PubMed ID: 8705327
[TBL] [Abstract][Full Text] [Related]
2. Signal-averaged ECG in patients after anthracycline therapy for childhood cancer.
Mladosievicová B; Foltinová A; Bernadic M; Hubka P; Petrásová H; Hulín I
Neoplasma; 1998; 45(1):40-5. PubMed ID: 9605001
[TBL] [Abstract][Full Text] [Related]
3. Assessment of anthracycline-induced cardiotoxicity with electrocardiography.
Horacek JM; Jakl M; Horackova J; Pudil R; Jebavy L; Maly J
Exp Oncol; 2009 Jun; 31(2):115-7. PubMed ID: 19550402
[TBL] [Abstract][Full Text] [Related]
4. [Frequency analysis of the QRS complex: a new method of detecting development of myocardial damage after anthracycline cytostatics].
Mladosievicova B; Foltinova A; Paulovic P; Petrasova H; Hulin I
Bratisl Lek Listy; 2000; 101(7):409-11. PubMed ID: 11059111
[TBL] [Abstract][Full Text] [Related]
5. Frequency-domain analysis of the QRS complex after treatment of childhood cancer with anthracycline cytostatics.
Mladosievicova B; Foltinova A; Luptak I; Petrasova H; Hulin I
Pediatr Cardiol; 2001; 22(6):478-82. PubMed ID: 11894149
[TBL] [Abstract][Full Text] [Related]
6. Signal-averaged electrocardiography in children with anthracycline-induced cardiomyopathy.
Vaksmann G; Gutierrez R; Duhamel A; Nelken B; Francart C; Kouakam C; Mazingue F; Rey C
Pediatr Cardiol; 2001; 22(6):494-8. PubMed ID: 11894153
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
Creutzig U; Diekamp S; Zimmermann M; Reinhardt D
Pediatr Blood Cancer; 2007 Jun; 48(7):651-62. PubMed ID: 17183582
[TBL] [Abstract][Full Text] [Related]
9. [Pathogenesis, prevention and detection of cardiotoxicity of anthracycline cytostatic agents].
Mladosievicová B; Hulín I; Krcméry V; Petrásová H; Kollárová H
Bratisl Lek Listy; 1994 Jul; 95(7):304-22. PubMed ID: 7812833
[TBL] [Abstract][Full Text] [Related]
10. Frequency-domain analysis of the signal-averaged electrocardiogram in hematological malignancies survivors.
Urbanova D; Urban L; Mikuskova E; Klincova M; Mladosievicova B
Bratisl Lek Listy; 2010; 111(3):144-9. PubMed ID: 20437824
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of anthracycline cardiotoxicity in children and adults.
Grenier MA; Lipshultz SE
Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
[TBL] [Abstract][Full Text] [Related]
12. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
[TBL] [Abstract][Full Text] [Related]
13. Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
Steinherz LJ; Steinherz PG; Tan CT; Heller G; Murphy ML
JAMA; 1991 Sep; 266(12):1672-7. PubMed ID: 1886191
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
15. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.
Toro-Salazar OH; Gillan E; O'Loughlin MT; Burke GS; Ferranti J; Stainsby J; Liang B; Mazur W; Raman SV; Hor KN
Circ Cardiovasc Imaging; 2013 Nov; 6(6):873-80. PubMed ID: 24097420
[TBL] [Abstract][Full Text] [Related]
16. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors.
Hudson MM; Rai SN; Nunez C; Merchant TE; Marina NM; Zalamea N; Cox C; Phipps S; Pompeu R; Rosenthal D
J Clin Oncol; 2007 Aug; 25(24):3635-43. PubMed ID: 17704413
[TBL] [Abstract][Full Text] [Related]
19. [Cardiotoxicity of antracycline treatment in the light of new biochemical diagnostic options].
Urbanová D; Mladosievicová B
Vnitr Lek; 2007 Jun; 53(6):669-77. PubMed ID: 17702127
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity of oncological treatment in children.
Kucharska W; Negrusz-Kawecka M; Gromkowska M
Adv Clin Exp Med; 2012; 21(3):281-8. PubMed ID: 23214190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
